Expression of DNA topoisomerase I, DNA topoisomerase II-alpha, and p53 in metastatic malignant melanoma

Human Pathology

Volumn 29, Issue 11, 1998, Pages 1240-1245

  Lynch, Beverly J ^b   Komaromy Hiller, Gabor ^b   Bronstein, Igor B ^b   Holden, Joseph A ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

DNA Topoisomerase I; DNA Topoisomerase II; Immunohistochemical staining, p53; Malignant melanoma

Indexed keywords

DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); PROTEIN P53;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; DNA STRAND BREAKAGE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; METASTASIS; PROTEIN EXPRESSION;

EID: 0031787528     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(98)90251-9     Document Type: Article

References (28)

1. Stopeck AT, Hersh EM, Akporiaye ET, et al: Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, JLA-B7, in patients with metastatic melanoma. J Clin Oncol 15:341-349, 1997
2. Keilholz U, Goey SH, Punt CJA, et al: Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: A randomized trial of the European organization for research and treatment of cancer melanoma cooperative group. J Clin Oncol 15:2579-2588, 1997
3. Hsiang YH, Liu LF: Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722-1726, 1988
4. Hsiang Y, Lihou MG, Liu LF: Arrest of replication forks by drug-stabilized topoisomerasc I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49:5077-5082, 1989
5. Nitiss JL, Wang JC: Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol Pharm 50:1095-1102, 1996
6. Madden KR, Champoux JJ: Overexpression of human topoisomerase I in baby hamster kidney cells: Hypersensitivity of clonal isolates to camptothecin. Cancer Res 52:525-532, 1992
7. Bjornsti MA, Benedetti P, Viglianti GA, et al: Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: Restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res 49:6318-6323, 1989
8. Sinha B: Topoisomerase inhibitors: A review of their therapeutic potential in cancer. Drugs 49:11-19, 1995
9. Pantazis P, Early JA, Mendoza JT, et al: Cytotoxic efficacy of 9-nitrocamptothecin in the treatment of human malignant melanoma cells in vitro. Cancer Res 54:771-776, 1994
10. Natelson EA, Giovanella BC, Verschraegen CF, et al: Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. Ann New York Acad Sci 803:224-230, 1996
11. Holden JA, Rahn MP, Jolles CJ, et al: Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinomas. J Clin Pathol Mol Pathol 50:247-253, 1997
12. Caserini C, Pratesi G, Tortoreto M, et al: Apoptosis as a determinant of tumor sensitivity of topotecan in human ovarian tumors: Preclinical in vitro/in vivo studies. Clin Cancer Res 3:955-961, 1997
13. Bronstein IB, Vorobyev S, Timofeev A, et al: Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies. Oncol Res 8:17-25, 1996
14. Lynch BJ, Guinee DN, Holden JA: Human DNA topoisomerase II-alpha: A new marker of cell proliferation in invasive breast cancer. HUM PATHOL 28:1180-1188, 1997
15. Woessner RD, Mattern MR, Mirabelli CK, et al: Proliferation- and cell cycle-dependent differences in the expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ 2:209-214, 1991
16. Holden JA, Perkins SL, Snow GW, et al: Immunohistochemical staining for DNA topoisomerase II in non-Hodgkin's lymphomas. Am J Clin Pathol 104:54-59, 1995
17. Heck MMS, Hittelman WN, Earnshaw WC: Differential expression of DNA topoisomerase I and II during the eukaryotic cell cycle. Proc Nad Acad Sci U S A 85:1086-1090, 1988
18. Brambilla E, Negoescu A, Gazzer S, et al: Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am J Pathol 149:1941-1952, 1996
19. Gelsleichter L, Gown AM, Zarbo RJ, et al: p53 and mdm-2 expression in malignant melanoma: An immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors. Mod Pathol 8:530-535, 1995
20. Holden JA: Human deoxyribonucleic acid topoisomerases: Molecular targets of anticancer drugs. Ann Clin Lab Sci 27:402-412, 1997
21. Leonard CJ, Canman CE, Kastan MB: The role of p53 in cell-cycle control and apoptosis: Implications of cancer. Import Adv Oncol 1995, pp 33-42
22. Rowinsky EK, Kaufmann SH: Topotecan in combination chemotherapy. Semin Oncol 24:20-26, 1997 (suppl 20)
23. Gobert C, Bracco L, Rossi F, et al: Modulation of DNA topoisomerase activity by p53. Biochemistry 35:5778-5786, 1996
24. Hwong C, Chen C, Shang H, et al: Increased synthesis and degradation of DNA topoisomerase I during the initial phase of human T lymphocyte proliferation. J Biol Chem 268:18982-18986, 1993
25. Mcleod HL, Keith WN: Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity. Br J Cancer 74:509-512, 1996
26. Lowe SW, Ruley HE, Jacks T, et al: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967, 1993
27. Creemers GJ, Bolis G, Scarfone G, et al: Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study. J Clin Oncol 14:3056-3061, 1996
28. Kruat EH, Crowley JJ, Wade JL, et al: Evaluation of topotecan in resistant and relapsing multiple myeloma: A southwest oncology group study. J Clin Oncol 16:589-592, 1998